PITTSBURGH, PA (April 5, 2017) -- Neuro Kinetics, Inc. (NKI), the global leader in clinical eye tracking and neural functional assessment, announces the issuance of its 19th U.S. patent covering eye pupil measurement and analysis. This new patent addresses separate stimulation of one pupil, while accurately measuring both the stimulated pupil and the un-stimulated pupil. Asymmetry in such a test is a key indicator of potentially serious health issues.
This award by the U.S. Patent and Trademarks Office, patent # 9,596,986, a "METHOD FOR MEASURING AND ANALYZING OCULAR RESPONSE IN A SUBJECT USING STABLE PUPILLARY PARAMETERS", expands NKI's protections around the use of video oculography (eye tracking technology), in particular the use of NKI's I-Portal® technology, to accurately measure the various dynamics of eye reflexes. This new patent builds on the protection provided in NKI's U.S. Patent #9,198,571, issued in December of 2015, which addresses pupil constriction and dilation as seen in images captured at greater than 60Hz.
"NKI made a strategic decision some years ago to engineer the most precise eye tracking tools available." says Howison Schroeder, Neuro Kinetics CEO and co-inventor. He continued, "This focus has led to highly accurate diagnostic tools to support the work of physicians."
The company's advances in precision eye measurements have proven prescient given growing concerns about concussion diagnosis and management. The company's ongoing clinical studies now demonstrate the effectiveness of I-Portal technology as a proxy for neural biomarkers for concussions. Last September, NKI announced a published paper authored jointly by researchers from leading clinics. Appearing in PLOS ONE, this compelling paper reported on the exceptional results of a U.S. Department of Defense-funded clinical trial classifying concussion patients using NKI's I-Portal® eye tracking and neuro-functional measurement technologies.
"This is an exciting time at Neuro Kinetics", says CTO and co-inventor, Alex Kiderman. "We are preparing to launch several new technologies and commence a large and pivotal clinical study to prove the diagnostic effectiveness of NKI's Concussion Score™." Should NKI's proposed objective, easy to interpret Concussion Score™ be cleared by the FDA, it would be another major breakthrough. The score is a derivative of neuro-biomarkers gathered using I-Portal® technology, and is expected to be the FDA's first-concussion clearance.
NKI's I-Portal systems integrate complex geometric algorithms, sophisticated software and highly engineered hardware including high quality digital cameras. The objective is to precisely track an individual's pupil and eye reflexes in horizontal and vertical planes, as well as torsionally (rotationally) in response to motion and to simple light forms that move or appear/disappear.
Research has identified over 200 diseases and medical conditions that are associated with abnormal eye movements. Sensitive, precise measurement of eye dynamics provides doctors with objective and early indicators of these health concerns.
To learn more about NKI, please visit http:/http://www.
VP Marketing & Sales
Neuro Kinetics, Inc.
The Science to See™
Neuro Kinetics, Inc. (NKI) is the leader in clinical eye-tracking and non-invasive neuro-otologic diagnostic testing. The eye is the portal to the brain and research has shown the detection of abnormal eye responses are used to diagnose more than 200 diseases and medical conditions.
With over 140 I-Portal installations, NKI's FDA cleared I-Portal® devices are sold to audiologists, ENT's, neurotologists, neuro-ophthalmologists and neurologists around the globe. The company's cleared patented diagnostic platforms include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services.